News & evidence
What is happening and how strong the evidence is: readouts, approvals, supply, failures and the money.
Who makes Lu-177, Ac-225, Mo-99 and Pb-212, and how tight each is.
Every trial ranked by evidence strength, endpoints as people out of 100.
Every trial result as people out of 100, medians explained, surrogate endpoints flagged.
The papers that changed practice, each explained: what it found and what to be careful about.
Where the evidence is published: scope, access model and the papers each venue carried.
Decisions, readouts, advisory committees, congresses.
Regulatory decisions, expected readouts, filings and deal closings by company.
Every dated filing, approval, CRL and label change.
Who bought or licensed what, for how much.
What did not work, and the lesson.
Every trial design as a card: when to use it, a worked example and its main risk.
Recent preprints per target, agent and technology, and which have since been published.
Fastest-growing topics in the literature, refreshed weekly from Europe PMC.
What the leading journals, regulators and news sources are saying this month.
What changed in Nuclide, and when.
When each automated feed last ran, what is stale, and the incident log.
How old is too old for each kind of record, and what is past due.
What changed on which record, field by field, from the git history.
Staleness, contradictions and registry mismatches, recomputed each build.
Every factual correction, what was wrong and how it was found.